Metabolic Associated Fatty Liver Disease (MAFLD)
Article Sidebar
Main Article Content
Abstract
Non-alcoholic fatty liver disease is the emerging chronic hepatitis in the modern era and commonly found in general clinical practice. The definition and criteria for diagnosis have been established and accepted in current standard guidelines. However, there is some misunderstanding between the terms of “NAFLD” and “NASH”. Additionally, the current “NAFLD” criteria have some limitations. Therefore, new nomenclature “metabolic (dysfunction) associated fatty liver disease (MAFLD)" and its diagnostic criteria have been recently proposed. This uses metabolic risks with the new criteria, which is different from NAFLD. Thus, physicians should know the dissimilarities and limitations although in reality, these are the same disease.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019; 17:748-755.e3.
Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389-98.
Teeratorn N, Piyachaturawat P, Thanapirom K, Chaiteerakij R, Sonsiri K,Komolmit P, et al.Screeningfor non-alcoholic fatty liver disease in community setting: A cohort study using controlled attenuation parameter-transient elastography. JGH Open 2019;4:245-50.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fattyliver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57.
FouadY, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Renaming 'NAFLD' to 'MAFLD'. Liver Int 2020;40:1254-61.
Wong VWS, Kanwal F. On the proposed definition of metabolic-associated fatty liver disease. Clin Gastroenterol Hepatol 2021;19:865-70.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202-9.
Ekstedt M, Franzén LE, Holmqvist M, Bendtsen P, Mathiesen UL, Bodemar G, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol2009;44:366-74.
Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.
Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65:1557-65.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.
Wong VW, Wong GL, Woo J, Abrigo JM, Chan CK, Shu SS et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19:2161-71.
Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40:2082-9.
Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk : a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19:2138-47.
Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14:889-919.
Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, et al. The times they are a-changin' (for NAFLD as well). J Hepatol 2020;73:1307-9.
Huang J, Kumar R, Wang M, Zhu Y, Lin S. MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?. J Hepatol 2020;73:1265-7.